Nurix Therapeutics, Inc. $NRIX Stake Lifted by KLP Kapitalforvaltning AS

KLP Kapitalforvaltning AS increased its stake in Nurix Therapeutics, Inc. (NASDAQ:NRIX) by 38.7% in the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 15,400 shares of the company’s stock after acquiring an additional 4,300 shares during the period. KLP Kapitalforvaltning AS’s holdings in Nurix Therapeutics were worth $175,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also made changes to their positions in the stock. Goldman Sachs Group Inc. boosted its holdings in shares of Nurix Therapeutics by 9.5% in the first quarter. Goldman Sachs Group Inc. now owns 507,471 shares of the company’s stock valued at $6,029,000 after acquiring an additional 44,002 shares in the last quarter. Rhumbline Advisers boosted its holdings in shares of Nurix Therapeutics by 7.0% in the first quarter. Rhumbline Advisers now owns 110,488 shares of the company’s stock valued at $1,313,000 after acquiring an additional 7,255 shares in the last quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC boosted its holdings in shares of Nurix Therapeutics by 8.7% in the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 159,530 shares of the company’s stock valued at $1,895,000 after acquiring an additional 12,817 shares in the last quarter. Millennium Management LLC boosted its holdings in shares of Nurix Therapeutics by 106.2% in the first quarter. Millennium Management LLC now owns 874,399 shares of the company’s stock valued at $10,388,000 after acquiring an additional 450,262 shares in the last quarter. Finally, MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. boosted its holdings in shares of Nurix Therapeutics by 11.9% in the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 49,804 shares of the company’s stock valued at $593,000 after acquiring an additional 5,286 shares in the last quarter.

Insider Buying and Selling

In other Nurix Therapeutics news, CFO Houte Hans Van sold 5,402 shares of the stock in a transaction that occurred on Friday, August 1st. The shares were sold at an average price of $11.03, for a total value of $59,584.06. Following the completion of the sale, the chief financial officer owned 35,512 shares in the company, valued at $391,697.36. This represents a 13.20% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, insider Gwenn Hansen sold 4,308 shares of the stock in a transaction that occurred on Wednesday, July 30th. The stock was sold at an average price of $12.01, for a total transaction of $51,739.08. Following the completion of the sale, the insider owned 69,023 shares of the company’s stock, valued at approximately $828,966.23. The trade was a 5.87% decrease in their position. The disclosure for this sale can be found here. In the last quarter, insiders sold 14,014 shares of company stock valued at $163,014. Insiders own 7.40% of the company’s stock.

Nurix Therapeutics Stock Performance

Shares of NASDAQ:NRIX opened at $10.39 on Tuesday. The company has a market cap of $798.78 million, a PE ratio of -3.50 and a beta of 2.33. Nurix Therapeutics, Inc. has a 52 week low of $8.18 and a 52 week high of $29.56. The firm has a 50 day simple moving average of $9.47 and a 200 day simple moving average of $10.51.

Nurix Therapeutics (NASDAQ:NRIX) last released its earnings results on Thursday, October 9th. The company reported ($1.03) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.84) by ($0.19). Nurix Therapeutics had a negative return on equity of 53.57% and a negative net margin of 292.50%.The company had revenue of $7.89 million during the quarter, compared to analysts’ expectations of $16.06 million. On average, equities analysts predict that Nurix Therapeutics, Inc. will post -2.99 earnings per share for the current year.

Analysts Set New Price Targets

Several research firms have recently issued reports on NRIX. UBS Group decreased their price objective on shares of Nurix Therapeutics from $30.00 to $26.00 and set a “buy” rating for the company in a report on Thursday, July 10th. Oppenheimer cut their target price on shares of Nurix Therapeutics from $30.00 to $28.00 and set an “outperform” rating for the company in a research note on Friday, October 10th. Stephens reissued an “overweight” rating and set a $30.00 target price on shares of Nurix Therapeutics in a research note on Thursday, July 10th. Needham & Company LLC reissued a “buy” rating and set a $27.00 target price on shares of Nurix Therapeutics in a research note on Monday. Finally, Piper Sandler cut their target price on shares of Nurix Therapeutics from $35.00 to $32.00 and set an “overweight” rating for the company in a research note on Friday, October 10th. One research analyst has rated the stock with a Strong Buy rating, twelve have assigned a Buy rating, three have given a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $27.79.

About Nurix Therapeutics

Nurix Therapeutics, Inc, a clinical stage biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule and cell therapies for the treatment of cancer, inflammatory conditions, and other diseases. The company develops NX-2127, an orally bioavailable Bruton's tyrosine kinase (BTK) degrader for the treatment of relapsed or refractory B-cell malignancies; NX-5948, an orally bioavailable BTK degrader for the treatment of relapsed or refractory B-cell malignancies and autoimmune diseases; and NX-1607, an orally bioavailable Casitas B-lineage lymphoma proto-oncogene-B (CBL-B) inhibitor for immuno-oncology indications.